Autopsy report · NCT03236649

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Because the clinical development plan has been changed.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 4 years 5 months before it stopped.
89 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Beijing Shenogen Biomedical Co., Ltd
Sponsor type: Industry
Conditions: Hepatocellular Carcinoma (HCC)
Interventions: Icaritin; Sorafenib Tosylate Tablets
Participants: 89
Sites: 26
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.